Patrick Daly

DocwireNews

According to a clinical trial published in The New England Journal of Medicine, &ldquo;rilzabrutinib showed a rapid and durable clinical activity that improved with length of treatment&rdquo; in patients with immune thrombocytopenia. The results of the trial supported the theory that the oral Bruton&rsquo;s tyrosine kinase inhibitor may support platelet count via &ldquo;decreased macrophage (Fc&gamma; receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.&rdquo;The phase I/II dose-finding trial, led by David J. Kuter, included 60 patients with immune thrombocytopenia, median platelet count of 5 &times; 103 per cubic millimeter, median duration of disease of 6.3 years, and a median of four previous immune thrombocytopenia therapies. Patients received escalating doses of rilzabrutinib over a 24-week period, with lowest and highest starting doses of 200 mg once daily and 400 mg twice daily, respectively. The primary outcomes of the study were safety and platelet response, which was defined as &ldquo;at least two consecutive platelet counts of &ge;50 &times; 103 per cubic millimeter and an increase from baseline of &ge;20 &times; 103 per cubic millimeter without the use of rescue medication.&rdquo;The investigators reported that all treatment-related adverse events observed in the trial were grade I to II and transient. Furthermore, &ldquo;there were no treatment-related bleeding or thrombotic events of grade II or higher,&rdquo; according to Kuter. After a median 167.5 days (range: 4&ndash;293) of treatment, 24 patients in the overall cohort (40%) and 18 patients who had started at the highest treatment dose (40%) met the primary platelet response threshold. Median time to first platelet count of &ge;50 &times; 103 per cubic millimeter was 11.5 days, and patients who met the primary response spent a mean of 65% of weeks with a platelet count above the threshold.In closing, the authors summarized that &ldquo;Rilzabrutinib was active and associated with only low-level toxic effects at all dose levels.&rdquo; They stated that a dose of 400 mg twice daily was selected for future testing.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Immune Thrombocytopenia Treatment With Rilzabrutinib

According to a clinical trial published in The New England Journal of Medicine, “rilzabrutinib showed a rapid and durable clinical activity that improved with length of ...

Immune Thrombocytopenia Treatment with Rilzabrutinib

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe